Lilly Zepbound / Mounjaro (tirzepatide) ~21% mean weight loss at ~72 weeks (top dose) Clear superiority vs Wegovy Growing long-term durability data Takeaway: Zepbound remains the benchmark every obesity drug must beat or meaningfully out-differentiate
Back when I was frequently recommending them, not much was known about their long-term side effects
Estimated to conclude on December 15, 2025, the trial assesses primary outcomes through changes from baseline in ADAS-Cog-11 and ADCS-ADL scores, measuring cognitive and functional abilities, respectively
Moreover, with the maximum oral dosage plasma levels are lower compared with the maximal subcutaneous dose (oral 20 mg yields plasma levels of ~25 nM, subcutaneous 1 mg yields plasma levels of ~45 nM ( Table 2 )
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911
Participants in these studies, who took oral weight loss medication Wegovy, experienced a significant reduction in body weight compared to those on a placebo
